[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-enicepatide-ct-388-roche-en":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":957,"_id":958,"_source":959,"_file":960,"_stem":961,"_extension":962},"\u002Fblog\u002Fen\u002Fenicepatide-ct-388-roche","en",false,"","Enicepatide (Roche's CT-388): what it is, and how it compares to semaglutide, tirzepatide, retatrutide and the amylins","This is general educational information, not medical advice and not a suggestion to obtain or use any substance. Enicepatide is an investigational drug that is not approved anywhere and cannot be legally bought or prescribed. Nothing here is dosing, stacking or purchasing guidance, and cross-trial numbers below come from separate studies — they are not head-to-head comparisons.","Research","tabler:flask-2","#6D5FC7","2026-07-24","July 2026","11 min","myPeptides Team","\u002Fassets\u002Fenicepatide_hero.png",{"type":19,"children":20,"toc":947},"root",[21,28,48,55,74,103,149,154,160,179,232,244,263,269,281,509,514,598,610,616,621,630,662,667,755,767,773,801,830,836,855,861],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,46],{"type":27,"value":32},"If you follow the obesity-drug pipeline, a new name showed up at the American Diabetes Association's 2026 meeting in New Orleans and refused to leave the headlines: ",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"enicepatide",{"type":27,"value":40},". It is Roche's, it is injectable, once a week, and in its Phase 2 trial it produced roughly ",{"type":22,"tag":34,"props":42,"children":43},{},[44],{"type":27,"value":45},"22.5% weight loss at 48 weeks",{"type":27,"value":47}," — the kind of number that only tirzepatide and retatrutide had reached before. This article is the plain-language version: what enicepatide is, where it sits next to semaglutide, tirzepatide, retatrutide, cagrilintide and eloralintide, how far along the research actually is, and whether it makes any sense to combine it with anything — the CagriSema question, and the biohacking-forum \"reta + cagri\" question.",{"type":22,"tag":49,"props":50,"children":52},"h2",{"id":51},"what-enicepatide-actually-is",[53],{"type":27,"value":54},"What enicepatide actually is",{"type":22,"tag":23,"props":56,"children":57},{},[58,60,65,67,72],{"type":27,"value":59},"Enicepatide is the newer name for a molecule you may already know by its code: ",{"type":22,"tag":34,"props":61,"children":62},{},[63],{"type":27,"value":64},"CT-388",{"type":27,"value":66}," (also written RO7795068). It came to Roche through the December 2023 acquisition of ",{"type":22,"tag":34,"props":68,"children":69},{},[70],{"type":27,"value":71},"Carmot Therapeutics",{"type":27,"value":73}," for about $2.7 billion, and Roche\u002FGenentech has been pushing it hard ever since.",{"type":22,"tag":23,"props":75,"children":76},{},[77,79,84,86,93,95,101],{"type":27,"value":78},"Mechanically, it is a ",{"type":22,"tag":34,"props":80,"children":81},{},[82],{"type":27,"value":83},"once-weekly subcutaneous dual GLP-1\u002FGIP receptor agonist",{"type":27,"value":85}," — one molecule that switches on two of the gut hormone receptors involved in appetite and blood sugar. That much it shares with ",{"type":22,"tag":87,"props":88,"children":90},"a",{"href":89},"\u002Fglp1\u002Ftirzepatide",[91],{"type":27,"value":92},"tirzepatide",{"type":27,"value":94},". What sets it apart is ",{"type":22,"tag":96,"props":97,"children":98},"em",{},[99],{"type":27,"value":100},"how",{"type":27,"value":102}," it hits those receptors:",{"type":22,"tag":104,"props":105,"children":106},"ul",{},[107,125],{"type":22,"tag":108,"props":109,"children":110},"li",{},[111,116,118,123],{"type":22,"tag":34,"props":112,"children":113},{},[114],{"type":27,"value":115},"Balanced, not lopsided.",{"type":27,"value":117}," Tirzepatide leans much harder on the GIP receptor than on GLP-1. Enicepatide is engineered for roughly ",{"type":22,"tag":96,"props":119,"children":120},{},[121],{"type":27,"value":122},"equal",{"type":27,"value":124}," activation of both — a genuinely different pharmacological profile, not just a stronger version of the same thing.",{"type":22,"tag":108,"props":126,"children":127},{},[128,133,135,140,142,147],{"type":22,"tag":34,"props":129,"children":130},{},[131],{"type":27,"value":132},"Signalling-biased.",{"type":27,"value":134}," This is the technical headline. Enicepatide is designed to trigger the useful \"cAMP\" signal inside the cell while recruiting very little ",{"type":22,"tag":34,"props":136,"children":137},{},[138],{"type":27,"value":139},"β-arrestin",{"type":27,"value":141}," — the protein that normally pulls a receptor back inside the cell and switches it off. Less of that internalisation means the receptor stays responsive longer, which is the mechanistic reason Roche gives for the drug's durable effect and the fact that weight loss had ",{"type":22,"tag":34,"props":143,"children":144},{},[145],{"type":27,"value":146},"not plateaued at 48 weeks",{"type":27,"value":148},".",{"type":22,"tag":23,"props":150,"children":151},{},[152],{"type":27,"value":153},"You do not need the biochemistry to use the takeaway: enicepatide is a refined dual agonist that tries to stay effective for longer per dose, rather than a brand-new class of drug.",{"type":22,"tag":49,"props":155,"children":157},{"id":156},"the-phase-2-numbers",[158],{"type":27,"value":159},"The Phase 2 numbers",{"type":22,"tag":23,"props":161,"children":162},{},[163,165,170,172,177],{"type":27,"value":164},"The data everyone reacted to came from a Phase 2 study (CT388-103) in ",{"type":22,"tag":34,"props":166,"children":167},{},[168],{"type":27,"value":169},"469 adults",{"type":27,"value":171}," with overweight or obesity, testing five doses from ",{"type":22,"tag":34,"props":173,"children":174},{},[175],{"type":27,"value":176},"4 mg to 24 mg",{"type":27,"value":178}," against placebo over 48 weeks. It showed a clean dose-response curve, and at the top dose:",{"type":22,"tag":104,"props":180,"children":181},{},[182,199],{"type":22,"tag":108,"props":183,"children":184},{},[185,190,192,197],{"type":22,"tag":34,"props":186,"children":187},{},[188],{"type":27,"value":189},"~22.5% placebo-adjusted weight loss at 48 weeks",{"type":27,"value":191}," (efficacy estimand), with ",{"type":22,"tag":34,"props":193,"children":194},{},[195],{"type":27,"value":196},"no plateau",{"type":27,"value":198}," yet — the curve was still heading down when the trial window closed.",{"type":22,"tag":108,"props":200,"children":201},{},[202,204,209,211,216,218,223,225,230],{"type":27,"value":203},"Among people on the 24 mg dose at week 48, ",{"type":22,"tag":34,"props":205,"children":206},{},[207],{"type":27,"value":208},"95.7%",{"type":27,"value":210}," lost at least 5% of their body weight, ",{"type":22,"tag":34,"props":212,"children":213},{},[214],{"type":27,"value":215},"87%",{"type":27,"value":217}," lost ≥10%, ",{"type":22,"tag":34,"props":219,"children":220},{},[221],{"type":27,"value":222},"47.8%",{"type":27,"value":224}," lost ≥20%, and ",{"type":22,"tag":34,"props":226,"children":227},{},[228],{"type":27,"value":229},"26.1%",{"type":27,"value":231}," lost ≥30%.",{"type":22,"tag":23,"props":233,"children":234},{},[235,237,242],{"type":27,"value":236},"It was not free of side effects. As with every drug in this class, the trouble is mostly gastrointestinal — nausea, vomiting, diarrhoea — and ",{"type":22,"tag":34,"props":238,"children":239},{},[240],{"type":27,"value":241},"discontinuations due to adverse events were 5.9%",{"type":27,"value":243},", versus 1.3% on placebo. That is a real number, but it sits in a normal range for potent incretin drugs.",{"type":22,"tag":23,"props":245,"children":246},{},[247,249,254,256,261],{"type":27,"value":248},"On the strength of that, Roche launched its Phase 3 programme, ",{"type":22,"tag":34,"props":250,"children":251},{},[252],{"type":27,"value":253},"ENITH",{"type":27,"value":255},", in early 2026, with a realistic launch somewhere around ",{"type":22,"tag":34,"props":257,"children":258},{},[259],{"type":27,"value":260},"2030",{"type":27,"value":262},". In other words: the efficacy signal is strong, and the timeline is long.",{"type":22,"tag":49,"props":264,"children":266},{"id":265},"how-it-differs-from-the-drugs-you-already-know",[267],{"type":27,"value":268},"How it differs from the drugs you already know",{"type":22,"tag":23,"props":270,"children":271},{},[272,274,279],{"type":27,"value":273},"Here is the landscape, and the single most useful thing to understand is that these molecules are not all doing the same job. Some hit incretin receptors (GLP-1, GIP, glucagon); others mimic ",{"type":22,"tag":34,"props":275,"children":276},{},[277],{"type":27,"value":278},"amylin",{"type":27,"value":280},", a different satiety hormone entirely.",{"type":22,"tag":282,"props":283,"children":284},"table",{},[285,314],{"type":22,"tag":286,"props":287,"children":288},"thead",{},[289],{"type":22,"tag":290,"props":291,"children":292},"tr",{},[293,299,304,309],{"type":22,"tag":294,"props":295,"children":296},"th",{},[297],{"type":27,"value":298},"Drug",{"type":22,"tag":294,"props":300,"children":301},{},[302],{"type":27,"value":303},"What it is",{"type":22,"tag":294,"props":305,"children":306},{},[307],{"type":27,"value":308},"Peak weight loss in its own trial",{"type":22,"tag":294,"props":310,"children":311},{},[312],{"type":27,"value":313},"Status",{"type":22,"tag":315,"props":316,"children":317},"tbody",{},[318,352,385,415,446,478],{"type":22,"tag":290,"props":319,"children":320},{},[321,330,342,347],{"type":22,"tag":322,"props":323,"children":324},"td",{},[325],{"type":22,"tag":34,"props":326,"children":327},{},[328],{"type":27,"value":329},"Enicepatide (CT-388)",{"type":22,"tag":322,"props":331,"children":332},{},[333,335,340],{"type":27,"value":334},"Balanced, signalling-biased ",{"type":22,"tag":34,"props":336,"children":337},{},[338],{"type":27,"value":339},"GLP-1\u002FGIP",{"type":27,"value":341}," dual agonist (Roche)",{"type":22,"tag":322,"props":343,"children":344},{},[345],{"type":27,"value":346},"~22.5% at 48 wks",{"type":22,"tag":322,"props":348,"children":349},{},[350],{"type":27,"value":351},"Phase 3 (ENITH)",{"type":22,"tag":290,"props":353,"children":354},{},[355,363,375,380],{"type":22,"tag":322,"props":356,"children":357},{},[358],{"type":22,"tag":34,"props":359,"children":360},{},[361],{"type":27,"value":362},"Semaglutide",{"type":22,"tag":322,"props":364,"children":365},{},[366,368,373],{"type":27,"value":367},"Pure ",{"type":22,"tag":34,"props":369,"children":370},{},[371],{"type":27,"value":372},"GLP-1",{"type":27,"value":374}," agonist (Novo — Wegovy\u002FOzempic)",{"type":22,"tag":322,"props":376,"children":377},{},[378],{"type":27,"value":379},"~15% at 68 wks",{"type":22,"tag":322,"props":381,"children":382},{},[383],{"type":27,"value":384},"Approved",{"type":22,"tag":290,"props":386,"children":387},{},[388,396,406,411],{"type":22,"tag":322,"props":389,"children":390},{},[391],{"type":22,"tag":34,"props":392,"children":393},{},[394],{"type":27,"value":395},"Tirzepatide",{"type":22,"tag":322,"props":397,"children":398},{},[399,404],{"type":22,"tag":34,"props":400,"children":401},{},[402],{"type":27,"value":403},"GIP\u002FGLP-1",{"type":27,"value":405}," dual agonist, GIP-leaning (Lilly — Zepbound\u002FMounjaro)",{"type":22,"tag":322,"props":407,"children":408},{},[409],{"type":27,"value":410},"~20–25%",{"type":22,"tag":322,"props":412,"children":413},{},[414],{"type":27,"value":384},{"type":22,"tag":290,"props":416,"children":417},{},[418,426,436,441],{"type":22,"tag":322,"props":419,"children":420},{},[421],{"type":22,"tag":34,"props":422,"children":423},{},[424],{"type":27,"value":425},"Retatrutide",{"type":22,"tag":322,"props":427,"children":428},{},[429,434],{"type":22,"tag":34,"props":430,"children":431},{},[432],{"type":27,"value":433},"GLP-1\u002FGIP\u002Fglucagon",{"type":27,"value":435}," triple agonist (Lilly)",{"type":22,"tag":322,"props":437,"children":438},{},[439],{"type":27,"value":440},"up to ~24%+",{"type":22,"tag":322,"props":442,"children":443},{},[444],{"type":27,"value":445},"Phase 3",{"type":22,"tag":290,"props":447,"children":448},{},[449,457,468,473],{"type":22,"tag":322,"props":450,"children":451},{},[452],{"type":22,"tag":34,"props":453,"children":454},{},[455],{"type":27,"value":456},"Cagrilintide",{"type":22,"tag":322,"props":458,"children":459},{},[460,462,466],{"type":27,"value":461},"Long-acting ",{"type":22,"tag":34,"props":463,"children":464},{},[465],{"type":27,"value":278},{"type":27,"value":467}," analog (Novo)",{"type":22,"tag":322,"props":469,"children":470},{},[471],{"type":27,"value":472},"modest alone; paired with semaglutide as CagriSema",{"type":22,"tag":322,"props":474,"children":475},{},[476],{"type":27,"value":477},"Phase 3 (as CagriSema)",{"type":22,"tag":290,"props":479,"children":480},{},[481,489,500,505],{"type":22,"tag":322,"props":482,"children":483},{},[484],{"type":22,"tag":34,"props":485,"children":486},{},[487],{"type":27,"value":488},"Eloralintide",{"type":22,"tag":322,"props":490,"children":491},{},[492,494,498],{"type":27,"value":493},"Selective ",{"type":22,"tag":34,"props":495,"children":496},{},[497],{"type":27,"value":278},{"type":27,"value":499}," agonist (Lilly)",{"type":22,"tag":322,"props":501,"children":502},{},[503],{"type":27,"value":504},"~9.5–20.1% at 48 wks",{"type":22,"tag":322,"props":506,"children":507},{},[508],{"type":27,"value":445},{"type":22,"tag":23,"props":510,"children":511},{},[512],{"type":27,"value":513},"A few honest words on each, because the table flattens real differences:",{"type":22,"tag":104,"props":515,"children":516},{},[517,534,557,582],{"type":22,"tag":108,"props":518,"children":519},{},[520,524,526,532],{"type":22,"tag":34,"props":521,"children":522},{},[523],{"type":27,"value":362},{"type":27,"value":525}," is the one-receptor original. Everything newer is, in some sense, an answer to \"can we beat pure GLP-1?\" Our ",{"type":22,"tag":87,"props":527,"children":529},{"href":528},"\u002Fglp1\u002Fsemaglutide",[530],{"type":27,"value":531},"semaglutide reference",{"type":27,"value":533}," has the background.",{"type":22,"tag":108,"props":535,"children":536},{},[537,541,543,548,550,555],{"type":22,"tag":34,"props":538,"children":539},{},[540],{"type":27,"value":395},{"type":27,"value":542}," was the first to prove two receptors beat one. Enicepatide's pitch is that it engages those same two receptors ",{"type":22,"tag":96,"props":544,"children":545},{},[546],{"type":27,"value":547},"more evenly and more durably",{"type":27,"value":549}," — see the ",{"type":22,"tag":87,"props":551,"children":552},{"href":89},[553],{"type":27,"value":554},"tirzepatide reference",{"type":27,"value":556}," for the incumbent it is measured against.",{"type":22,"tag":108,"props":558,"children":559},{},[560,564,566,572,574,580],{"type":22,"tag":34,"props":561,"children":562},{},[563],{"type":27,"value":425},{"type":27,"value":565}," adds a third receptor, glucagon, and currently posts the highest incretin weight-loss numbers of all — we covered its latest Phase 3 read-outs in ",{"type":22,"tag":87,"props":567,"children":569},{"href":568},"\u002Fblog\u002Fretatrutide-triumph-2-3-results",[570],{"type":27,"value":571},"Retatrutide TRIUMPH-2 and TRIUMPH-3",{"type":27,"value":573}," and the full picture lives on our ",{"type":22,"tag":87,"props":575,"children":577},{"href":576},"\u002Fglp1\u002Fretatrutide",[578],{"type":27,"value":579},"retatrutide reference",{"type":27,"value":581},". Enicepatide is not trying to out-muscle it; it is trying to get similar results from a cleaner two-receptor design.",{"type":22,"tag":108,"props":583,"children":584},{},[585,590,592,596],{"type":22,"tag":34,"props":586,"children":587},{},[588],{"type":27,"value":589},"Cagrilintide and eloralintide",{"type":27,"value":591}," are not incretins at all — they are ",{"type":22,"tag":34,"props":593,"children":594},{},[595],{"type":27,"value":278},{"type":27,"value":597}," drugs, working through a separate satiety pathway. That distinction is the whole reason the next section exists.",{"type":22,"tag":23,"props":599,"children":600},{},[601,603,608],{"type":27,"value":602},"One caution you should carry through all of this: ",{"type":22,"tag":34,"props":604,"children":605},{},[606],{"type":27,"value":607},"none of these numbers are head-to-head.",{"type":27,"value":609}," Different trials, different lengths, different populations. A 22.5% in one study and a 24% in another do not settle which drug is \"stronger\" — only a direct trial can do that, and most of those have not been run.",{"type":22,"tag":49,"props":611,"children":613},{"id":612},"can-you-combine-it-cagrisema-reta-cagri-and-roches-own-answer",[614],{"type":27,"value":615},"Can you combine it? CagriSema, \"reta + cagri\", and Roche's own answer",{"type":22,"tag":23,"props":617,"children":618},{},[619],{"type":27,"value":620},"This is the question that fills forums, and it is worth answering carefully, because the popular framing is a little confused.",{"type":22,"tag":23,"props":622,"children":623},{},[624],{"type":22,"tag":625,"props":626,"children":629},"img",{"alt":627,"src":628},"An incretin-style ribbon and a small amylin loop feeding one injection pen — the incretin-plus-amylin combination idea","\u002Fassets\u002Fenicepatide_combo.png",[],{"type":22,"tag":23,"props":631,"children":632},{},[633,635,640,642,646,648,653,655,660],{"type":27,"value":634},"First, the taxonomy. ",{"type":22,"tag":34,"props":636,"children":637},{},[638],{"type":27,"value":639},"CagriSema is not two GLP-1 drugs",{"type":27,"value":641}," — it is one GLP-1 drug (semaglutide) plus one ",{"type":22,"tag":34,"props":643,"children":644},{},[645],{"type":27,"value":278},{"type":27,"value":647}," drug (cagrilintide) in a single pen, hitting two ",{"type":22,"tag":96,"props":649,"children":650},{},[651],{"type":27,"value":652},"different",{"type":27,"value":654}," hormone systems. That is the important pattern: the entire industry is converging on ",{"type":22,"tag":34,"props":656,"children":657},{},[658],{"type":27,"value":659},"\"incretin + amylin\"",{"type":27,"value":661}," as the next step, because the two pathways suppress appetite in complementary ways rather than piling onto the same receptor.",{"type":22,"tag":23,"props":663,"children":664},{},[665],{"type":27,"value":666},"Once you see that, the combination question answers itself:",{"type":22,"tag":104,"props":668,"children":669},{},[670,693,731],{"type":22,"tag":108,"props":671,"children":672},{},[673,678,680,685,687,691],{"type":22,"tag":34,"props":674,"children":675},{},[676],{"type":27,"value":677},"Stacking two incretin drugs is mostly pointless.",{"type":27,"value":679}," Enicepatide already covers GLP-1 and GIP. Adding ",{"type":22,"tag":87,"props":681,"children":682},{"href":528},[683],{"type":27,"value":684},"semaglutide",{"type":27,"value":686}," (more GLP-1) or ",{"type":22,"tag":87,"props":688,"children":689},{"href":89},[690],{"type":27,"value":92},{"type":27,"value":692}," (more of the same two) does not open a new mechanism — it just doubles the receptor you are already hitting, which tends to add side effects without adding much benefit. That is why no serious programme develops \"GLP-1 plus another GLP-1.\"",{"type":22,"tag":108,"props":694,"children":695},{},[696,701,703,708,710,715,717,722,724,729],{"type":22,"tag":34,"props":697,"children":698},{},[699],{"type":27,"value":700},"The rational partner is an amylin.",{"type":27,"value":702}," And here is the tell: Roche is doing exactly this. Alongside enicepatide it is developing ",{"type":22,"tag":34,"props":704,"children":705},{},[706],{"type":27,"value":707},"petrelintide",{"type":27,"value":709},", an amylin analog (~9% weight loss on its own at 42 weeks), and in ",{"type":22,"tag":34,"props":711,"children":712},{},[713],{"type":27,"value":714},"mid-2026 it started a Phase 2 trial of the two combined",{"type":27,"value":716}," — a fixed-dose enicepatide + petrelintide, explicitly to chase more weight loss with better tolerability. Novo's version of that idea is ",{"type":22,"tag":34,"props":718,"children":719},{},[720],{"type":27,"value":721},"CagriSema",{"type":27,"value":723},"; Lilly's is ",{"type":22,"tag":34,"props":725,"children":726},{},[727],{"type":27,"value":728},"tirzepatide + eloralintide",{"type":27,"value":730},". Roche's is enicepatide + petrelintide. Same recipe, three kitchens.",{"type":22,"tag":108,"props":732,"children":733},{},[734,739,741,746,748,753],{"type":22,"tag":34,"props":735,"children":736},{},[737],{"type":27,"value":738},"The biohacking \"reta + cagri\" stack",{"type":27,"value":740}," — ",{"type":22,"tag":87,"props":742,"children":743},{"href":576},[744],{"type":27,"value":745},"retatrutide",{"type":27,"value":747}," plus cagrilintide — is the grey-market echo of the same logic: a triple incretin plus an amylin. Mechanistically it rhymes with what the companies are testing. Practically, it is a different animal: there is ",{"type":22,"tag":34,"props":749,"children":750},{},[751],{"type":27,"value":752},"no controlled human safety data for the do-it-yourself version",{"type":27,"value":754},", the side effects (nausea, vomiting, dehydration, and the discontinuations that go with them) stack too, and every vial in that scenario is unregulated material of unverified identity and purity. The fact that a combination makes pharmacological sense in a sponsored trial does not make a self-mixed version safe, dosed correctly, or legal.",{"type":22,"tag":23,"props":756,"children":757},{},[758,760,765],{"type":27,"value":759},"So: can you combine enicepatide? On paper, the sensible combination is enicepatide ",{"type":22,"tag":34,"props":761,"children":762},{},[763],{"type":27,"value":764},"with an amylin",{"type":27,"value":766},", not with another GLP-1 — and that combination is being built by Roche itself, under clinical supervision, years before anyone can buy either piece.",{"type":22,"tag":49,"props":768,"children":770},{"id":769},"what-this-means-for-you-today",[771],{"type":27,"value":772},"What this means for you today",{"type":22,"tag":23,"props":774,"children":775},{},[776,778,783,785,791,793,799],{"type":27,"value":777},"Be clear-eyed about the timeline. Enicepatide is ",{"type":22,"tag":34,"props":779,"children":780},{},[781],{"type":27,"value":782},"investigational",{"type":27,"value":784},". It is not approved anywhere, you cannot get a prescription for it, and the Phase 3 programme points to a possible launch around 2030. Anything sold online right now as \"enicepatide\" or \"CT-388\" is, by definition, unapproved grey-market material of unknown identity and purity — a committee slide deck and a clinical trial do not vouch for a vial a stranger mailed you. If you want the wider legal picture, our pillar on ",{"type":22,"tag":87,"props":786,"children":788},{"href":787},"\u002Fare-peptides-legal",[789],{"type":27,"value":790},"whether peptides are legal",{"type":27,"value":792}," walks through the categories, and ",{"type":22,"tag":87,"props":794,"children":796},{"href":795},"\u002Fwhat-are-peptides",[797],{"type":27,"value":798},"what peptides are",{"type":27,"value":800}," is the ground-up primer.",{"type":22,"tag":23,"props":802,"children":803},{},[804,806,812,814,820,822,828],{"type":27,"value":805},"For the drugs people actually do track today, the neutral part is the arithmetic. If you keep a record of what you have, at what concentration, and when, ",{"type":22,"tag":87,"props":807,"children":809},{"href":808},"\u002Fpeptides-list",[810],{"type":27,"value":811},"our peptide tracker",{"type":27,"value":813}," is built for exactly that; if reconstitution is the shaky step, ",{"type":22,"tag":87,"props":815,"children":817},{"href":816},"\u002Fcalculator",[818],{"type":27,"value":819},"our calculator",{"type":27,"value":821}," turns a target dose into the units on the syringe once you know the vial strength and the bacteriostatic water you added; and because these are weekly injections whose levels rise and fall between shots, ",{"type":22,"tag":87,"props":823,"children":825},{"href":824},"\u002Fplotter",[826],{"type":27,"value":827},"the level plotter",{"type":27,"value":829}," draws that curve. None of that is a recommendation to use anything — it is the maths, kept honest.",{"type":22,"tag":49,"props":831,"children":833},{"id":832},"bottom-line",[834],{"type":27,"value":835},"Bottom line",{"type":22,"tag":23,"props":837,"children":838},{},[839,841,846,848,853],{"type":27,"value":840},"Enicepatide (CT-388) is Roche's balanced, signalling-biased GLP-1\u002FGIP agonist, and its ~22.5% Phase 2 weight loss earns it a real seat at the table next to tirzepatide and retatrutide — with a cleaner two-receptor design and a longer runway to market. The combination story is the more interesting one: the field has moved on to ",{"type":22,"tag":34,"props":842,"children":843},{},[844],{"type":27,"value":845},"incretin + amylin",{"type":27,"value":847},", and Roche's own answer is enicepatide ",{"type":22,"tag":34,"props":849,"children":850},{},[851],{"type":27,"value":852},"plus petrelintide",{"type":27,"value":854},", not enicepatide plus another GLP-1. Stacking two incretins is redundant; the DIY \"reta + cagri\" version borrows the right idea and none of the safety data. For now, enicepatide is a drug to watch, not a drug to get — because you can't, and the version a forum sells you is not the version that produced these numbers.",{"type":22,"tag":49,"props":856,"children":858},{"id":857},"sources",[859],{"type":27,"value":860},"Sources",{"type":22,"tag":104,"props":862,"children":863},{},[864,877,888,899,911,923,935],{"type":22,"tag":108,"props":865,"children":866},{},[867,869],{"type":27,"value":868},"Roche, ",{"type":22,"tag":87,"props":870,"children":874},{"href":871,"rel":872},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-01-27",[873],"nofollow",[875],{"type":27,"value":876},"Positive Phase II results for its dual GLP-1\u002FGIP receptor agonist CT-388 (enicepatide)",{"type":22,"tag":108,"props":878,"children":879},{},[880,881],{"type":27,"value":868},{"type":22,"tag":87,"props":882,"children":885},{"href":883,"rel":884},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-06-01",[873],[886],{"type":27,"value":887},"New data advancing its obesity portfolio at the ADA 2026 Scientific Sessions",{"type":22,"tag":108,"props":889,"children":890},{},[891,892],{"type":27,"value":868},{"type":22,"tag":87,"props":893,"children":896},{"href":894,"rel":895},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[873],[897],{"type":27,"value":898},"Positive Phase II results for petrelintide, an amylin analog",{"type":22,"tag":108,"props":900,"children":901},{},[902,904],{"type":27,"value":903},"Medical Dialogues, ",{"type":22,"tag":87,"props":905,"children":908},{"href":906,"rel":907},"https:\u002F\u002Fmedicaldialogues.in\u002Fnews\u002Findustry\u002Fpharma\u002Froche-obesity-drug-enicepatide-delivers-227-weight-loss-in-mid-stage-trial-challenges-wegovy-zepbound-172251",[873],[909],{"type":27,"value":910},"Roche obesity drug enicepatide delivers 22.7% weight loss in mid-stage trial",{"type":22,"tag":108,"props":912,"children":913},{},[914,916],{"type":27,"value":915},"PMC \u002F peer-reviewed, ",{"type":22,"tag":87,"props":917,"children":920},{"href":918,"rel":919},"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC12771327\u002F",[873],[921],{"type":27,"value":922},"Effects of CT-388, a once-weekly signaling-biased dual GLP-1\u002FGIP receptor agonist",{"type":22,"tag":108,"props":924,"children":925},{},[926,928],{"type":27,"value":927},"Lilly, ",{"type":22,"tag":87,"props":929,"children":932},{"href":930,"rel":931},"https:\u002F\u002Flilly.gcs-web.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated",[873],[933],{"type":27,"value":934},"Selective amylin agonist eloralintide — Phase 2 results",{"type":22,"tag":108,"props":936,"children":937},{},[938,940],{"type":27,"value":939},"HCPLive, ",{"type":22,"tag":87,"props":941,"children":944},{"href":942,"rel":943},"https:\u002F\u002Fwww.hcplive.com\u002Fview\u002Fcagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial",[873],[945],{"type":27,"value":946},"CagriSema achieves 22.7% weight loss in Phase 3 REDEFINE 1",{"title":7,"searchDepth":948,"depth":948,"links":949},2,[950,951,952,953,954,955,956],{"id":51,"depth":948,"text":54},{"id":156,"depth":948,"text":159},{"id":265,"depth":948,"text":268},{"id":612,"depth":948,"text":615},{"id":769,"depth":948,"text":772},{"id":832,"depth":948,"text":835},{"id":857,"depth":948,"text":860},"markdown","content:blog:en:enicepatide-ct-388-roche.md","content","blog\u002Fen\u002Fenicepatide-ct-388-roche.md","blog\u002Fen\u002Fenicepatide-ct-388-roche","md"]